Last reviewed · How we verify
DWC202404, DWC202314P
DWC202404, DWC202314P is a botulinum toxin type A inhibitor Small molecule drug developed by Daewoong Pharmaceutical Co. LTD.. It is currently in Phase 3 development for Upper limb spasticity in adults, Cervical dystonia in adults, Blepharospasm in adults.
DWC202404 is a botulinum toxin type A inhibitor.
DWC202404 is a botulinum toxin type A inhibitor. Used for Upper limb spasticity in adults, Cervical dystonia in adults, Blepharospasm in adults.
At a glance
| Generic name | DWC202404, DWC202314P |
|---|---|
| Sponsor | Daewoong Pharmaceutical Co. LTD. |
| Drug class | botulinum toxin type A inhibitor |
| Target | botulinum toxin type A |
| Modality | Small molecule |
| Therapeutic area | Neurology |
| Phase | Phase 3 |
Mechanism of action
It works by inhibiting the release of acetylcholine at the neuromuscular junction, leading to muscle relaxation and reduction of muscle spasms.
Approved indications
- Upper limb spasticity in adults
- Cervical dystonia in adults
- Blepharospasm in adults
Common side effects
- Dry mouth
- Headache
- Injection site pain
- Muscle weakness
- Nausea
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- DWC202404, DWC202314P CI brief — competitive landscape report
- DWC202404, DWC202314P updates RSS · CI watch RSS
- Daewoong Pharmaceutical Co. LTD. portfolio CI
Frequently asked questions about DWC202404, DWC202314P
What is DWC202404, DWC202314P?
How does DWC202404, DWC202314P work?
What is DWC202404, DWC202314P used for?
Who makes DWC202404, DWC202314P?
What drug class is DWC202404, DWC202314P in?
What development phase is DWC202404, DWC202314P in?
What are the side effects of DWC202404, DWC202314P?
What does DWC202404, DWC202314P target?
Related
- Drug class: All botulinum toxin type A inhibitor drugs
- Target: All drugs targeting botulinum toxin type A
- Manufacturer: Daewoong Pharmaceutical Co. LTD. — full pipeline
- Therapeutic area: All drugs in Neurology
- Indication: Drugs for Upper limb spasticity in adults
- Indication: Drugs for Cervical dystonia in adults
- Indication: Drugs for Blepharospasm in adults
- Compare: DWC202404, DWC202314P vs similar drugs
- Pricing: DWC202404, DWC202314P cost, discount & access